Avoid the stress of overpaying for a stock or missing an opportunity by using the right tools and insights to evaluate Avidity Biosciences Inc before investing.

In this article, we go over a few key elements for understanding Avidity Biosciences Inc’s stock price such as:

• Avidity Biosciences Inc’s current stock price and volume
• Why Avidity Biosciences Inc’s stock price changed recently
• Upgrades and downgrades for RNA from analysts
• RNA’s stock price momentum as measured by its relative strength

About Avidity Biosciences Inc (RNA)

Before we jump into Avidity Biosciences Inc’s stock price, history, target price and what caused it to recently dip, let’s take a look at some background.

Avidity Biosciences, Inc. is a biopharmaceutical company. The Company is engaged in delivering a new class of ribonucleic acid (RNA) therapeutics called antibody oligonucleotide conjugates (AOCs). The AOCs are designed to combine the specificity of monoclonal antibodies with the precision of oligonucleotide therapies to address targets and diseases previously unreachable with existing RNA therapies. Its advancing and expanding pipeline has three programs in clinical development. AOC 1001 is designed to treat people with myotonic dystrophy type 1 (DM1) and is in phase I/II development with the ongoing MARINA open label extension study (MARINA-OLE). AOC 1044 is designed for people with Duchenne muscular dystrophy and is in phase I/II development with the EXPLORE44 trial. AOC 1020 is designed to treat people living with facioscapulohumeral muscular dystrophy (FSHD) and is in Phase I/II development with the FORTITUDE trial.

Want to learn more about Avidity Biosciences Inc’s stock? Click the button below to subscribe to A+ Investor and get access to everything you need to know about Avidity Biosciences Inc.

Avidity Biosciences Inc’s Stock Price as of Market Close

As of August 22, 2024, 4:00 PM, CST, Avidity Biosciences Inc’s stock price was $42.86.

Avidity Biosciences Inc is down 4.81% from its previous closing price of $45.02.

During the last market session, Avidity Biosciences Inc’s stock traded between $42.90 and $46.00. Currently, there are 106.93 million shares of Avidity Biosciences Inc stock available for purchase.

Unfortunately, Avidity Biosciences Inc’s P/E ratio is not significant enough to use for stock price evaluation. We recommend investors evaluate other financial metrics to understand its overall valuation.

Avidity Biosciences Inc Stock Price History

Avidity Biosciences Inc’s (RNA) price is currently down 5.98% so far this month.

During the month of August, Avidity Biosciences Inc’s stock price has reached a high of $47.50 and a low of $37.04.

Over the last year, Avidity Biosciences Inc has hit prices as high as $48.80 and as low as $4.83. Year to date, Avidity Biosciences Inc’s stock is up 93.13%.

Sign Up to Receive a Free Special Report Showing How A+ Grades Can Help You Make Smarter Investment Decisions

What Caused Avidity Biosciences Inc Stock’s Price to Dip?

Stock prices are primarily based on seller supply and buyer demand. But have you ever wondered about what other factors affect a stock's price?

When an analyst changes their opinion of a stock by upgrading or downgrading their rating, it often leads to a sudden stock price adjustment. As of August 21, 2024, there was 1 analyst who downgraded Avidity Biosciences Inc’s stock and 6 analysts who upgraded over the last month.

Additionally, you'll want to evaluate Avidity Biosciences Inc’s financial health and valuation. Investors can use AAII's Value Grade, which combines six key valuation metrics like P/E and P/S ratios for a comprehensive analysis to conduct analysis on Avidity Biosciences Inc’s valuation and financial health. This approach mitigates the limitations of single-metric evaluations.

Avidity Biosciences Inc’s current valuation based on AAII’s Value Grade is a F, which means it is considered to be Ultra Expensive.

Learn how to evaluate stocks with AAII Grades and Scores with A+ Investor today.

Lastly, news and media coverage as well as recent press reports about the company or its industry may cause stock prices to fluctuate. You can check out the most recent news articles about Avidity Biosciences Inc (RNA) by visiting AAII Stock Evaluator.

Relative Price Strength of Avidity Biosciences Inc

Relative price strength measures a stock's performance against the market, helping investors identify stocks that are outperforming benchmarks.

For AAII’s Momentum Grade, a weighted relative price strength is calculated. Follow this link to learn more about the Momentum Grade.

As of August 21, 2024, Avidity Biosciences Inc has a weighted four-quarter relative price strength of 54.16%, which translates to a Momentum Score of 98 and is considered to be Very Strong.

Want to learn more about how Avidity Biosciences Inc is graded based on AAII’s composite scores for value, growth, quality and earnings estimate revisions? Subscribe to A+ Investor today.

Avidity Biosciences Inc Stock Price: Bottom Line

As of August 22, 2024, Avidity Biosciences Inc’s stock price is $42.86, which is down 4.81% from its previous closing price.

AAII advises against making stock decisions based solely on price or past returns. Instead, consider a variety of metrics, fundamentals, and analytics to evaluate a stock like Avidity Biosciences Inc stock prices are influenced by market supply and demand and offer just a snapshot of a company's overall health.

Subscribing to AAII's A+ Investor provides access to comprehensive analytics and insights for confident investing.